TSG Advice Partners LLC Buys 5,869 Shares of AbbVie Inc. $ABBV

by · The Cerbat Gem

TSG Advice Partners LLC purchased a new position in shares of AbbVie Inc. (NYSE:ABBV – Free Report) during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 5,869 shares of the company’s stock, valued at approximately $1,477,000.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Burk Holdings LLC acquired a new position in AbbVie in the second quarter valued at about $30,000. Marquette Asset Management LLC increased its holdings in shares of AbbVie by 52.2% in the second quarter. Marquette Asset Management LLC now owns 140 shares of the company’s stock worth $35,000 after acquiring an additional 48 shares in the last quarter. IMG Wealth Management Inc. increased its holdings in shares of AbbVie by 3,060.0% in the second quarter. IMG Wealth Management Inc. now owns 158 shares of the company’s stock worth $40,000 after acquiring an additional 153 shares in the last quarter. Principia Wealth Advisory LLC raised its position in shares of AbbVie by 38.9% during the second quarter. Principia Wealth Advisory LLC now owns 157 shares of the company’s stock worth $40,000 after purchasing an additional 44 shares during the period. Finally, Tacita Capital Inc acquired a new stake in shares of AbbVie during the second quarter worth about $42,000. 70.23% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on ABBV shares. Barclays lifted their price objective on AbbVie from $300.00 to $325.00 and gave the company an “overweight” rating in a report on Wednesday, October 21st. Citigroup boosted their price objective on AbbVie from $230.00 to $260.00 and gave the company a “neutral” rating in a research report on Wednesday, July 15th. Sanford C. Bernstein reissued a “market perform” rating and set a $275.00 target price on shares of AbbVie in a research note on Monday. Erste Group Bank upgraded shares of AbbVie from a “hold” rating to a “buy” rating in a report on Wednesday, August 5th. Finally, The Goldman Sachs Group lifted their price target on shares of AbbVie from $258.00 to $294.00 and gave the company a “neutral” rating in a research note on Friday, October 23rd. One research analyst has rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and six have issued a Hold rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $294.67.

View Our Latest Stock Report on AbbVie

Key Stories Impacting AbbVie

Here are the key news stories impacting AbbVie this week:

  • Positive Sentiment: Expanded migraine partnership: AbbVie and Brise Pharmaceuticals announced a global license agreement to advance next-generation migraine treatments, potentially worth up to $757 million. The deal adds another growth opportunity to AbbVie’s neuroscience pipeline. AbbVie, Brise Expand Migraine Drug Partnership
  • Positive Sentiment: Positive migraine data: A Phase 3 study published in The Lancet Neurology reportedly delivered a favorable result, supporting the commercial potential of AbbVie’s migraine portfolio. AbbVie Lands Phase 3 Migraine Study Win
  • Positive Sentiment: Analyst optimism increased: Cantor Fitzgerald raised its price target to $325, while RBC, Canaccord Genuity, Leerink Partners and Morgan Stanley lifted targets to $330, $338, $342 and $346, respectively. The revisions reflect confidence in AbbVie’s immunology transition and raised outlook. Analysts Increase Forecasts on AbbVie
  • Positive Sentiment: Strong operating performance: Third-quarter revenue rose 10.3% to $17.4 billion, while adjusted EPS of $3.82 exceeded expectations. Skyrizi, Rinvoq and neuroscience products are offsetting Humira’s decline, and management raised its 2026 revenue and earnings outlook. ABBV Q3 Earnings Call Highlights
  • Positive Sentiment: Dividend increase: AbbVie raised its quarterly dividend 5.2% to $1.82 per share, signaling confidence in cash flow and reinforcing the stock’s income appeal.
  • Neutral Sentiment: Legal win: AbbVie prevailed in a lawsuit against the U.S. Department of Health and Human Services concerning drug-price controls, potentially reducing near-term regulatory uncertainty. AbbVie Wins Drug Price Control Lawsuit
  • Negative Sentiment: Transition and valuation risks remain: Humira sales continue to decline, leaving investors dependent on Skyrizi, Rinvoq and pipeline launches to sustain growth. After a sharp rally, ABBV’s elevated valuation and proximity to its 52-week high may also be prompting profit-taking despite the positive updates. AbbVie’s Humira Era Is Fading

AbbVie Stock Performance

NYSE ABBV opened at $288.66 on Tuesday. AbbVie Inc. has a 52 week low of $190.75 and a 52 week high of $298.74. The stock’s 50 day moving average price is $269.81 and its two-hundred day moving average price is $237.57. The stock has a market capitalization of $509.99 billion, a price-to-earnings ratio of 49.68, a PEG ratio of 1.31 and a beta of 0.24.

AbbVie (NYSE:ABBV – Get Free Report) last issued its quarterly earnings results on Friday, October 30th. The company reported $3.82 earnings per share for the quarter, topping the consensus estimate of $3.73 by $0.09. AbbVie had a net margin of 9.80% and a negative return on equity of 422.07%. The company had revenue of $17.40 billion during the quarter, compared to analysts’ expectations of $17.32 billion. During the same period last year, the business earned $1.86 EPS. The business’s quarterly revenue was up 10.3% on a year-over-year basis. On average, equities research analysts forecast that AbbVie Inc. will post 13.92 EPS for the current year.

AbbVie Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, February 16th. Investors of record on Friday, January 15th will be given a $1.82 dividend. This represents a $7.28 dividend on an annualized basis and a yield of 2.5%. This is an increase from AbbVie’s previous quarterly dividend of $1.73. The ex-dividend date of this dividend is Friday, January 15th. AbbVie’s payout ratio is 119.10%.

Insider Transactions at AbbVie

In other AbbVie news, EVP Nicholas Donoghoe sold 32,710 shares of AbbVie stock in a transaction on Friday, August 14th. The shares were sold at an average price of $250.00, for a total value of $8,177,500.00. Following the sale, the executive vice president directly owned 74,430 shares in the company, valued at approximately $18,607,500. The trade was a 30.53% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Insiders own 0.06% of the company’s stock.

AbbVie Company Profile

(Free Report)

AbbVie Inc (NYSE: ABBV) is a global biopharmaceutical company that discovers, develops and commercializes medicines and other healthcare products. Its portfolio focuses on immunology, oncology, neuroscience, aesthetics and eye care, serving patients and healthcare providers in markets around the world.

The company’s key products include immunology medicines such as Skyrizi and Rinvoq; neuroscience treatments including Vraylar, Ubrelvy and Qulipta; and oncology products such as Imbruvica and Venclexta.

See Also